Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sk-bioscience-co-ltd" target="_blank" data-smartkarma-citation="entities:31484:1" rel="noopener">SK Bioscience (302440 KS)</a> has initiated global Phase 3 clinical trial of GBP410, a 21-valent pneumococcal conjugate vaccine (PCV21) candidate, with topline result expected in 2027.</li>
<li>IDT Biologika recorded revenue of KRW118B in 1Q25, up from KRW111B in 4Q24. Considering 1Q25 momentum, IDT seems to be on track to meet 2025 guidance of KRW410B.</li>
<li>1Q25 base business revenue increased 62% YoY to KRW36B. Operating loss of the base business narrowed to KRW26B from a loss of KRW28B in year-ago quarter.</li>
</ul>



SK Bioscience (302440 KS) has initiated global Phase 3 clinical trial of GBP410, a 21-valent pneumococcal conjugate vaccine (PCV21) candidate, with topline result expected in 2027.
IDT Biologika recorded revenue of KRW118B in 1Q25, up from KRW111B in 4Q24. Considering 1Q25 momentum, IDT seems to be on track to meet 2025 guidance of KRW410B.
1Q25 base business revenue increased 62% YoY to KRW36B. Operating loss of the base business narrowed to KRW26B from a loss of KRW28B in year-ago quarter.


SK Bioscience (302440 KS): Dual Engines Led Growth Strategy Is on Track; Solid 1Q25 Performance

APAC IPOs & Placements, Aequitas Research

Nicholas Tan

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/beijing-geekplus-technology-co-ltd-geek" target="_blank" data-smartkarma-citation="entities:35636:1" rel="noopener">Geek+ (1678559D CH)</a> is looking to raise up to US$200m in its upcoming Hong Kong IPO.</li>
<li>It is the leader in the global autonomous mobile robots (AMR) market. </li>
<li>In this note, we provide updates on the firm’s past performance.</li>
</ul>



Geek+ (1678559D CH) is looking to raise up to US$200m in its upcoming Hong Kong IPO.
It is the leader in the global autonomous mobile robots (AMR) market. 
In this note, we provide updates on the firm’s past performance.


Beijing Geekplus Pre-IPO: PHIP Updates - Losses Continue to Narrow but Growth Decelerating

Chief Executive Officer, Emmer Capital Partners Limited

Manishi Raychaudhuri

Chief Executive Officer

Emmer Capital Partners Limited

Emmer Capital Partners is an Asia Pacific focused financial advisory firm engaging in strategic financial asset allocation advice, bespoke thematic research and advising early-stage companies and connecting them to investors. Emmer Capital provides macro-economic and multi-asset investment strategy inputs to institutions, family offices, private wealth managers, private equity, and corporate boards directly and through independent research platforms. Emmer Capital also advises a wide range of startup companies on fund raising and business strategy. Emmer Capital's active engagement with the print and electronic media reaches a broad spectrum of investors across the globe.

Cross Asset Strategy

<ul>
<li>Despite ongoing military conflicts and a trade war, Asia ex Japan headline valuations are remarkably stable and robust. North Asia's and India's valuations and growth forecasts are healthier than ASEAN's</li>
<li>North Asia's and India's EPS growth and ROE profile are sturdier. Korea's, Taiwan's, China's and India's forecast EPS growth (2026E) are 15-17%. Conversely, Singapore's, Thailand's, Malaysia's and Philippines' are 4.5-8.5%.</li>
<li>Taiwan and India (15-15.5%) have highest forecast ROEs. Indonesia (13.9%), Philippines (12.6%), HK/China (10-11%) follows. All others have single digit forecast ROE. Our overweights on Korea, HK/CN, India seem justified.</li>
</ul>


Despite ongoing military conflicts and a trade war, Asia ex Japan headline valuations are remarkably stable and robust. North Asia's and India's valuations and growth forecasts are healthier than ASEAN's
North Asia's and India's EPS growth and ROE profile are sturdier. Korea's, Taiwan's, China's and India's forecast EPS growth (2026E) are 15-17%. Conversely, Singapore's, Thailand's, Malaysia's and Philippines' are 4.5-8.5%.
Taiwan and India (15-15.5%) have highest forecast ROEs. Indonesia (13.9%), Philippines (12.6%), HK/China (10-11%) follows. All others have single digit forecast ROE. Our overweights on Korea, HK/CN, India seem justified.


Asian Equities: Growth and ROE Driving Valuation Divergence; North Asia Pockets Robust, ASEAN Feeble

Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Croma Security Solutions Group / Equity Bottom-Up

<ul>
<li>Welcome to the first in a new series of thematic reports We will be focusing on undervalued and under researched small caps across a range of sectors, reflecting the challenges and general market apathy.</li>
<li>We start with a general small cap growth theme.</li>
<li>Further editions may focus on other sectors, in the pipeline, potentially, recruitment, and engineering.</li>
</ul>


Welcome to the first in a new series of thematic reports We will be focusing on undervalued and under researched small caps across a range of sectors, reflecting the challenges and general market apathy.
We start with a general small cap growth theme.
Further editions may focus on other sectors, in the pipeline, potentially, recruitment, and engineering.


Hybridan Research: Sector Piece: Undervalued, Under Researched Small Caps

External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>We visited the integrated unit (IU) of Andhra Cements (ACL) at Dachepalli, in the Palnadu district of Andhra Pradesh</li><li>Sagar Cements (SGC) owns 90% stake in its subsidiary Andhra Cements, which it had acquired through NCLT in 2023</li><li>Under SGC, ACL’s capacity enhancement, refurbishment, and cost reduction programs are progressing well, and are expected to turn around its profitability</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

We visited the integrated unit (IU) of Andhra Cements (ACL) at Dachepalli, in the Palnadu district of Andhra PradeshSagar Cements (SGC) owns 90% stake in its subsidiary Andhra Cements, which it had acquired through NCLT in 2023Under SGC, ACL’s capacity enhancement, refurbishment, and cost reduction programs are progressing well, and are expected to turn around its profitabilityContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sagar Cements: Andhra Cements Revamp on the Cards. Maintain ADD